Contact
searchSearch
HMP Global
Login
Quiz

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases

11/27/2023

Related Content

James Cleary, MD, PhD
Videos
Zenocutuzumab Expands Targeted Treatment Options for NRG1 Fusion-Positive Cholangiocarcinoma
07/28/2026
James Cleary, MD, PhD
James Cleary, MD, PhD, discusses the recent FDA approval of zenocutuzumab for patients with NRG1 fusion–positive cholangiocarcinoma and the importance of incorporating RNA-based next-generation sequencing into routine molecular testing to...
James Cleary, MD, PhD, discusses the recent FDA approval of zenocutuzumab for patients with NRG1 fusion–positive cholangiocarcinoma and the importance of incorporating RNA-based next-generation sequencing into routine molecular testing to...
James Cleary, MD, PhD, discusses...
07/28/2026
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Cholangiocarcinoma
07/08/2026
Stephanie Holland
Results from the phase 2 eNRGy trial demonstrated that zenocutuzumab produced durable clinical activity with a favorable safety profile in patients with advanced NRG1 fusion-positive cholangiocarcinoma, supporting HER2/HER3-targeted therapy...
Results from the phase 2 eNRGy trial demonstrated that zenocutuzumab produced durable clinical activity with a favorable safety profile in patients with advanced NRG1 fusion-positive cholangiocarcinoma, supporting HER2/HER3-targeted therapy...
Results from the phase 2 eNRGy...
07/08/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma Despite Limited Overall Efficacy in Biliary Tract Cancer
06/25/2026
Stephanie Holland
Results from the phase 2 MoST-CIRCUIT trial demonstrated that nivolumab plus ipilimumab produced modest overall activity in advanced biliary tract cancers but demonstrated encouraging efficacy in patients with gallbladder carcinoma,...
Results from the phase 2 MoST-CIRCUIT trial demonstrated that nivolumab plus ipilimumab produced modest overall activity in advanced biliary tract cancers but demonstrated encouraging efficacy in patients with gallbladder carcinoma,...
Results from the phase 2...
06/25/2026
Oncology
Tanios Bekaii-Saab, MD
Videos
Pemigatinib Improves Outcomes Compared With Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma
06/18/2026
Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, discusses results from the phase 3 FIGHT-302 study which showed that first-line pemigatinib significantly improved progression-free survival, objective response rate, and duration of response compared with...
Tanios Bekaii-Saab, MD, discusses results from the phase 3 FIGHT-302 study which showed that first-line pemigatinib significantly improved progression-free survival, objective response rate, and duration of response compared with...
Tanios Bekaii-Saab, MD,...
06/18/2026
Oncology

Recent News

FDA Approval
FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot
09/23/2026
Stephanie Holland
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s...
09/23/2026
Oncology
News
NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening
09/23/2026
Stephanie Holland
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized...
09/23/2026
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use